Abstract
Hepatocellular carcinoma (HCC) is a global healthcare challenge, which affects more than 815,000 new cases every year. Activated hepatic stellate cells (aHSCs) remain the principal cells that drive HCC onset and growth. aHSCs suppress the anti-tumor immune response through interaction with different immune cells. They also increase the deposition of the extracellular matrix proteins, challenging the reversion of fibrosis and increasing HCC growth and metastasis. Therapy for HCC was reported to activate HSCs, which could explain the low efficacy of current treatments. Conversely, recent studies aimed at the deactivation of HSCs show that they have been able to inhibit HCC growth. In this review article, we discuss the role of aHSCs in HCC pathophysiology and therapy. Finally, we provide suggestions for the experimental implementation of HSCs in HCC therapies.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference81 articles.
1. Hepatocellular Carcinoma-Related Mortality in the USA, 1999–2018;Ramani;Am. J. Dig. Dis.,2022
2. Chidambaranathan-Reghupaty, S., Fisher, P.B., and Sarkar, D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. 2021, 149, 1–61. Adv. Cancer Res.
3. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer;Affo;Annu. Rev. Pathol. Mech. Dis.,2017
4. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets;Zhang;World J. Gastroenterol.,2016
5. Kanel, G.C., and Korula, J. (2011). General Aspects of the Liver and Liver Diseases. Atlas Liver Pathol., 3–15.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献